Through a comparison of the CA125 levels on immune cell subsets of ovarian cancer patients versus healthy donors, we demonstrate that our new technique can serve as a novel diagnostic platform for detection and monitoring of ovarian cancer. This evidence concerns the gene MUC16 and ovarian carcinoma.